AMDL's Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment
November 29 2007 - 1:27PM
PR Newswire (US)
TUSTIN, Calif., Nov. 29 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. (Jade), is an international
biopharma company and today announced that Jade has received the
Brand Excellence Award from the Chinese Federation of Industry and
Commerce for its state-of-the-art anti-aging treatment Goodnak(R).
The Chinese Federation hailed Goodnak(R) as a breakthrough Chinese
medical/beauty product at a gala ceremony in Shenzhen, China, where
the award was presented to Jade executives, who said it is set to
become one of the premiere beauty products in China. Goodnak(R) is
a high quality injectable anti-aging & skin care product that
contains an amalgam of various therapeutic elements including human
placental histosolution (HPH). Jade has begun selling Goodnak(R)
through wholesale distribution channels that service high-end
beauty salon and plastic surgery hospitals and medical cosmetology
institutions. Goodnak product information is available on Jade
Pharma's product specific website: http://www.jade-amdl.com/. Gary
Dreher, CEO of AMDL, noted that AMDL is now a health care company,
with noteworthy pharmaceutical products for treating disease, a
diagnostic company, with a test to detect cancer at early stages,
and a nutraceutical Company, with significant products for
wellness. "We are confident that Goodnak(R) will become a large
part of our success both short and longterm," Mr. Dreher said.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. About Jade: Jade has access to
the fastest growing pharmaceutical and consumer market in the
world: China. AMDL, through its Jade subsidiaries, currently holds
licenses for 133 products that are manufactured as large volume
injection fluids, tablets and other related products. It currently
manufactures over 20 key generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing
Practice (CGMP) standards. Forward-Looking Statements: This news
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: AMDL Investor Relations, Mr. Paul Knopick,
+1-949-707-5365, Voice Mail, +1-714-505-4460 Web site:
http://www.amdl.com/ http://www.jade-amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024